Wilms‘ Tumor Gene 1 (WT1)–loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial
/in Dendritic Cells, Endometrial Cancer, International PublicationsDendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian CancerMyeloid-derived suppressor cells in glioma
/in Glioblastoma, International Publications, IOZK VeröffentlichungenDendritic cell-based immunotherapy in ovarian cancer
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian CancerSuperior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma
/in Dendritic Cells, International Publications, NSCLC[Immunotherapy and hyperthermia for the treatment of patients with advanced or recurrent colorectal cancer]
/in Colorectal Cancer, Hyperthermia, International PublicationsDendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: clinical trial protocol
/in Dendritic Cells, Glioblastoma, International Publications[The effect of immunotherapy and hyperthermia on patients with advanced or recurrent breast cancer]
/in Breast Cancer, Hyperthermia, International PublicationsDendritic cells, inflammation, and breast cancer
/in Breast Cancer, Dendritic Cells, International PublicationsIMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer